Are placebo-controlled studies required in order to prove efficacy of antidepressants?

World Journal of Biological Psychiatry

Volumn 6, Issue 3, 2005, Pages 130-131

  Möller, Hans Jurgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; PLACEBO; NEW DRUG;

CLINICAL RESEARCH; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HUMAN; LICENSING; MEDICAL ETHICS; POLITICS; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SOCIAL CONTROL; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; EPIDEMIOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; BIAS (EPIDEMIOLOGY); DRUG APPROVAL; DRUGS, INVESTIGATIONAL; HELSINKI DECLARATION; HUMANS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33644692091     PISSN: 15622975     EISSN: None     Source Type: Journal    
DOI: 10.1080/15622970510030108     Document Type: Editorial

References (2)

1. EMEA. 2001. EMEA/CPMP position statement on the use of placebo in clinical trials with regard to the revised Declaration of Helsinki [www.emea.eu.int/pdfs/human/press/pos/1742401en.pdf].
2. World Medical Association. 2000. Declaration of Helsinki, 5th (Edinburgh) amendment [www.wma.net/e/policy/b3.htm].